Skip to main content
daunorubicin and cytarabine liposome for injection
Top Navigation
Cookie Policy
Terms of use
Privacy Statement
Contact Us
English
En
Français
English
daunorubicin and cytarabine liposome for injection
English
En
Français
English
Home
AML overview
AML overview
WHO Classification: high-risk AML subtypes
Evolution of D+C treatment
About CombiPlex
®
About CombiPlex
®
Mechanism of action
Made in Canada: The story of VYXEOS
®
The clinical evidence
The clinical evidence
Efficacy results
5-year results
The safety profile
The administration
The administration
Administering VYXEOS
®
Resources
Contact us
Terms of use
Privacy statement
Product Monograph
Safety information
Product Monograph
Safety information
Cookie Policy
